Enzyme activity studies demonstrated that fetuin-B is a potent and highly specific inhibitor of the zona proteinase ovastacin, which cleaves ZP protein 2 (ZP2) and thus mediates definitive ZP hardening.
Introduction
The zona pellucida (ZP) is a glycoprotein matrix surrounding the oocyte. It comprises three ZP proteins (ZP1-ZP3) (Bleil and Wassarman, 1980; Wassarman, 1988) . After fertilization of the oocyte the cortical granule proteinase ovastacin, also termed sperm acrosomal SLLP1 binding protein (SAS1B), cleaves the ZP protein 2 (ZP2) resulting in a definitive block of fertilization, also known as ZP hardening (Burkart et al., 2012; Sachdev et al., 2013) . Fetuin-B, a liver-derived plasma protein, efficiently inhibits this spurious release of ovastacin before fertilization and thus prevents premature ZP hardening (Ducibella et al., 1988; Dietzel et al., 2013; Stöcker et al., 2014) . Thereby fetuin-B maintains the ZP penetrability and plays an essential role in fertilization. In the absence of fetuin-B, ZP hardening occurs before fertilization, and sperm cannot penetrate the oocyte. Consequently, female Fetub −/− mice are completely and permanently infertile (Dietzel et al., 2013 (Dietzel et al., , 2016a ). Here we asked if the fertility of Fetub −/− females could be restored by an additional ovastacin deficiency (Astl −/− ), underscoring fetuin-B as a promising contraceptive target. Further we investigated if the pharmacological fetuin-B downregulation by antisense oligonucleotides (ASO) would result in reversible infertility, effectively mediating contraception.
ASO are short chemically modified oligonucleotides that bind their complementary target mRNA by Watson-Crick base pairing (Bennett and Swayze, 2010) . So-called second-generation gapmer ASO are composed of a central block of phosphorothioate deoxyribonucleotides that promote RnaseH binding followed by degradation of the target mRNA (Monia et al., 1993) . The central block is flanked by 2′-O-(2-methoxyethyl)ribonucleotides protecting the internal block from degradation (Teplova et al., 1999) . Phosphorothioate bonds between the nucleotides further increase the stability of ASO. Clinical trials demonstrated the efficacy of ASO therapy in rheumatoid arthritis, cardiovascular disease and diabetes (Sewell et al., 2002; Kastelein et al., 2006; Graham et al., 2013) . Liver and kidney accumulate most ASO and thus also show the highest off-target effects (Geary et al., 2009 ). Liver targeting is highly advantageous in the case of fetuin-B, because it is a liver-derived plasma protein. Therefore ASO-mediated fetuin-B down-regulation seems a promising novel contraceptive strategy.
Classical hormone-mediated contraception has intrinsic disadvantages despite proven success and worldwide application in human and animal medicine. Undesired effects of hormonal contraceptives include thrombosis, breast cancer, depression, bone fractures and a reduction in the ovarian reserve (Clemons and Goss, 2001; Svendal et al., 2012; Birch Petersen et al., 2015; Lopez et al., 2015; Tepper et al., 2016) . Nevertheless, there is an urgent need for contraception to reduce the high number of unintended pregnancies noted in the USA (50%) and worldwide (40%) (Finer and Henshaw, 2006; Yazdkhasti et al., 2015) . Contraception should prevent pregnancies as well as be reversible and well tolerated. Apart from classical hormonal contraception targeting embryo implantation, current contraceptive research attempted to prevent the fusion of sperm and oocyte. In female hamsters and mice, monoclonal antibodies against ZP2 and ZP3 were administered to inhibit sperm binding (Shivers et al., 1972; East et al., 1984 East et al., , 1985 Lou et al., 1995; Greenhouse et al., 1999) . Alternatively, ZP peptides were used for an active immunization (Paterson et al., 2002) . This treatment has always the associated risk of autoimmune reaction and thus permanent infertility. A recent publication demonstrated that ZP2 peptide-coated beads sequester sperm in the uterus and thereby prevent fertilization without pathologies (Avella et al., 2016) .
Here we targeted the liver-derived plasma protein fetuin-B to achieve reversible infertility in female mice. Pharmacological downregulation using fetuin-B ASO efficiently down-regulated hepatic synthesis and caused infertility in female mice that had less than 10 µg/ml serum fetuin-B. Fertility was restored within 2 months of stopping ASO treatment, and mice gave birth to healthy and fertile offspring.
Materials and Methods

Ethical approval
All animal experiments were approved by the animal welfare committee of the Landesamt für Natur-, Umwelt-, und Verbraucherschutz (LANUV) of the state of North Rhine Westphalia, Germany. Animal maintenance, handling and treatment of the mice were performed according to the Federation for Laboratory Animal Science Associations (FELASA) recommendations. The mice were housed in controlled humidity and temperature on a constant 12 hours light dark cycle. Food and water were given ad libitum. ) and 800 bp (Astl
).
IVF
The IVF protocol was followed as previously described (Dietzel et al., 2013) . Oocytes from Fetub +/+ and Fetub +/− females showed no differences in IVF rate (Dietzel et al., 2013) . Thus Fetub +/+ and Fetub +/− derived oocytes were pooled as 'wildtype' to save experimental animals. Two independent IVF studies were performed. One study was used to assess the IVF rate in Fetub −/− , Astl −/− females (FVB and C57BL/6 mixed genetic background, n = 7). Female fetuin-B wildtypes (C57BL/6, n = 6) served as control.
To determine the permissive serum fetuin-B concentration required for contraception, female Fetub +/− mice (C57BL/6, n = 17) were used. Prior IVF females were treated for 4 weeks with ASO as described in 'Serum fetuin-B down-regulation by ASO application'. Six mice each were treated with fetuin-B ASO or control oligonucleotide. Six females were inseminated without ASO treatment (untreated control).
ASO chemistry and synthesis
A fetuin-B 5-10-5 2-methoxyethyl gapmer with phosphorothioate backbone (5′-TAC ATT TCA TTG TGT GTG TC-3′, ION 637072), was synthesized and purified with a final purity of 95% by Ionis Pharmaceuticals, Inc. (Carlsbad, CA, USA) as previously described (Baker et al., 1997 ) at 5 mg/ml or 10 mg/ml and sterile filtered using 0.2 µm pore size filter cartridges (VWR, Radnor, USA). ASO concentration was verified by absorbance measurement at 260 nm (Biospectrometer, Eppendorf, Hamburg, Germany). An oligonucleotide 2′-MOE ASO 5′-CCT TCC CTG AAG GTT CCT CC-3′ (ION 141923), of the same chemical and mechanistic class as the fetuin-B compound but not complementary to any known sequence, was used for control injections before IVF.
Serum fetuin-B down-regulation by ASO treatment
Fetuin-B ASO (5 or 10 mg/ml in PBS) were injected s.c. into 6-13 week old C57BL/6 mice (Fetub +/+ , Fetub
) at 50 mg/kg or 100 mg/kg body weight. The control mice were treated with PBS. A single bolus was injected every other day for 14 days, and every third day thereafter. ASO intake and organ distribution was confirmed by high performance liquid chromatography mass spectrometry as previously described (Prakash et al., 2015) . To determine serum fetuin-B concentration, blood samples were drawn from the vena saphena before, during and after ASO treatment.
Serum fetuin-B determination
Blood was clotted and centrifuged at 2000g for 10 min. Serum was harvested and snap-frozen in liquid nitrogen. For immunoblots, 0.3 µl murine serum was separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis using mini gels (10% acrylamide, 5 × 8 × 0. 
Mating of fetuin-B ASO-treated females
Twelve female mice (Fetub +/− , Fetub +/+ ) were injected repetitively with 100 mg/kg fetuin-B ASO and ten females (Fetub +/− , Fetub +/+ ) with PBS.
A single bolus was injected every other day for 14 days, and every third day thereafter. Twenty days after the first injection one PBS-treated female, one fetuin-B ASO-treated female and one male were placed in mating cages (n = 12). The PBS-treated females served as internal control to prove fertility of the male and to exclude the possibility that mouse handling influenced the reproductive behavior. Mating success and pregnancy of females were scored by daily plug check and palpation. For plug analysis plug fragments were isolated from the inner side of the vaginal cavity and dissolved in 10 µl PBS. Vaginal smears were prepared and microscopically analyzed.
Offspring of fetuin-B ASO-treated females
Three week old pups were weighed, litter size was noted and retro-orbital blood was sampled. Serum fetuin-B was determined by immunoblot as described. Serum fetuin-B concentrations were normalized to serum fetuin-B of an untreated 3 week old wildtype pup. All mice were genotyped for fetuin-B.
Fetub and Gapdh RNA quantification
After 3 weeks of PBS or fetuin-B ASO treatment, six females from each group were euthanized, and the liver, one kidney and one ovary were removed to determine the fetuin-B mRNA expression level. Organs were harvested into RNA stabilization reagent (RNAlater, Qiagen, Hilden, Germany) and incubated for 24 h at 4°C. Afterwards organs were snap frozen using liquid nitrogen until the procedure was continued. RNA was extracted (GeneJet Purification Kit, Thermo Fisher Scientific), followed by cDNA synthesis (Maxima first strand cDNA synthesis kit for reverse transcription quantitative polymerase chain reaction (RT-qPCR), Thermo Fisher Scientific) and RT-qPCR (Maxima SYBR Green/Fluorescein qPCR Master Mix (2x), Thermo Fisher Scientific). The following primers were used for RNA quantification: Fetub forward 5′-CAACATCTAACAACGTCTAGCC-3′ and reverse 5′-GTAAGCCACTCTGCCAAATC-3′; Glycerinaldehyd-3-phosphate dehydrogenase (Gapdh) forward 5′-AGATGGTGATGGGCTTCCC-3′ and reverse 5′-GGCAAATTCAACGGCACAGT-3′. Each RT-qPCR was performed in duplicate. For quantification Fetub values were normalized to Gapdh values.
Serum chemistry
Serum was prepared from the blood of female mice. Tissues from these mice were also used for Fetub and Gapdh mRNA quantification. Aspartate (AST) and alanine aminotransferase (ALT) were measured using a Vitros 350 analyzer and reagents (Ortho Clinical Diagnostics, NJ, USA).
Statistical analysis
Data were analyzed using GraphPad Prism 5.0c (GraphPad Software, San Diego, CA, USA) as detailed in the figure legends. The two-tailed Student's t-test was performed to compare litter sizes of PBS and ASOtreated mice and to calculate the differences in mRNA expression. The two-tailed Mann Whitney t-test was used to compare the litter sizes of Fetub
, Astl −/− and Astl −/− females as well as for comparison of ALT and AST activity in sera of PBS and ASO-treated mice. A P-value < 0.05 was regarded as statistically significant.
Results
Confirming fetuin-B as a target for contraception in vivo
Fetub −/− single deficient females are infertile (Fig. 1A ). An additional ovastacin deficiency restored fertility despite the fetuin-B deficiency. Fetub
, Astl −/− females produced offspring confirming ovastacin proteinase as a prime molecular target of fetuin-B, a proteinase inhibitor. Thus, in the absence of the target ovastacin proteinase, the lack of the regulating inhibitor is of no further consequence. Figure 1A shows that the average litter size of Fetub
, Astl −/− females mated with double deficient or wildtype males (5.6 ± 3.5 and 6.2 ± 3.7 pups per litter, respectively) were similar to Astl −/− females (4.7 ± 1.5 and 5.3 ± 0.6, respectively) with proved diminished fertility (Burkart et al., 2012; Sachdev et al., 2013) . The male genotype had no influence on the litter size. However, the variation in the litter sizes was higher in female Fig. S1A ). The offspring appeared healthy at birth and attained similar weights at weaning compared to the offspring of Astl −/− females ( Supplementary Fig. S1B ) indicating normal lactation of the females and therefore a normal post-natal development. We asked if we could find a diminished fertility in vitro as the in vivo data suggested, and as was previously shown for the Astl −/− females. IVF rates of Fetub
, Astl −/− mice were generally very high at 95 ± 1% compared with IVF rates attained with wildtype-derived oocytes at 61 ± 22% (Fig. 1B) . Interestingly, following IVF of oocytes from Fetub
females, unfertilized intact oocytes were never observed. If oocytes were unfertilized, they were damaged and contained coagulated cytoplasm and cell fragmentation. Reduced litter sizes after natural mating on the one hand and the exceedingly high IVF rates on the other hand indicated a defect in embryo implantation or development following successful fertilization. It is likely that the ZP of Fetub
oocytes was the critical factor for an impaired fertility. Microscopic observation showed a high proportion of empty zonae (Fig. 1D sperm bound to the ZP of Fetub −/− , Astl −/− derived oocytes than to wildtype oocytes. Supplementary Fig. S2 shows that less than 10 sperm usually remained attached to wildtype embryos following IVF. In contrast, more than 100 sperm remained attached to Fetub −/− , Astl −/− derived oocytes.
Fetuin-B ASO mediated down-regulation causes infertility
The recovery of fertility in Fetub
, Astl −/− females underscored the decisive role of fetuin-B in fertilization, rendering fetuin-B a potential target for contraception. We analyzed the fertility of female mice undergoing fetuin-B down-regulation by ASO. Figure 2 illustrates the dose finding study assessing the effect of single or repetitive fetuin-B ASO boli. A single bolus of 50 mg/kg or 100 mg/kg body weight reduced serum fetuin-B to 90 ± 10% and 74 ± 3% of baseline level, respectively ( Fig. 2A) . Control injections with PBS did not change serum fetuin-B. It took up to 3 weeks for the serum fetuin-B level to recover. Ten repetitive boli of 50 mg/kg fetuin-B ASO reduced serum fetuin-B to 33 ± 6% at day 20 (Fig. 2B) . Upon mating these females became pregnant indicating that the fetuin-B down-regulation was insufficient to block fertilization (Supplementary Table S1 ). Ten repetitive boli of an increased dose of 100 mg/kg fetuin-B ASO down-regulated serum fetuin-B to 8 ± 6% of baseline at day 20 (Fig. 2B) . Figure 3A illustrates a typical serum fetuin-B down-regulation and recovery time course starting with 20 repetitive boli of 100 mg/kg within 50 days and the following washout period. Serum fetuin-B of all mice (n = 12) at day 0 was analyzed by immunoblot employing commercial recombinant mouse fetuin-B as a standard ( Supplementary Fig. S3A ). Figure 3B -M show absolute serum fetuin-B concentrations determined by densitometry. ASO treatment down-regulated serum fetuin-B to 3-19 µg/ml after 20 days of ASO treatment. After treatment cessation it took 93 ± 19 days until serum fetuin-B of ASO-treated females returned to baseline level. In contrast, serum fetuin-B was unchanged in PBStreated females. Upon mating, all PBS-injected female mice became pregnant within 13 days (Supplementary Table S2 ), while the fetuin-B ASO-treated females (11 out of 12) did not become pregnant following ASO-mediated serum fetuin-B down-regulation. Daily plug checks suggested that mating had occurred. In comparison, unstable vaginal plugs were frequently observed in the ASO-treated females (Fig. 3B, D, F , G, H, I), but not in PBS control mice. Microscopic unstable plug analysis detected cornified epithelial cells suggesting that the mice were in estrus and ovulating (Fig. 3N) . Sperm was also detected ( Fig. 3O and P) indicating mating despite unstable plug formation. Only one out of twelve females became pregnant during the fetuin-B ASO treatment (Fig. 3M) : this mouse had the least down-regulated serum fetuin of about 19 µg/ml at day 20. The Fetub mRNA measurement in the liver confirmed the serum fetuin-B protein determination. In ASO-treated animals, Fetub mRNA dropped to 12.1 ± 3.1% in comparison to PBS-treated mice (Fig. 4A) . For good measure, Fetub mRNA was quantified in kidney and ovary. In PBS and ASO-treated females fetuin-B expression was detected at a very low level in ovary (2.0 ± 1.2% versus 2.3 ± 1%, respectively) and kidney (0.6 ± 0.2% versus 0.3 ± 0.1%, respectively) suggesting that both organs were negligible concerning fetuin-B mRNA expression level in the liver. Published literature reports ASO toxicity in the liver (Zanardi et al., 2012) . We assessed hepatotoxicity by measuring ALT and AST activity. Figure 4B and C show that the treatment with 10 repetitive 100 mg/kg fetuin-B ASO boli increased ALT and AST activity in comparison to the PBS-treated control mice. The elevated aminotransferase activities indicate modest liver toxicity, most likely caused by non-specific target side effects of ASO. Nevertheless, the females of both treatment groups appeared equally healthy and were indistinguishable in behavior and body weight (Supplementary Fig. S3B ).
Contraceptive effect of fetuin-B ASO is reversible
Next, we tested if fetuin-B ASO mediated infertility was reversible. By 60.3 ± 35.9 days following the ASO treatment all mice became pregnant. Seven females had a second litter within 30 days after the first delivery, and three females delivered two litters within 42-55 days, similar to published values for C57BL/6J mice of 37.3 ± 6.2 days (The Jackson Laboratory, http://phenome.jax.org). In two mice, copulation Figure 2 Serum fetuin-B down-regulation by fetuin-B antisense oligonucleotide (ASO). Serum fetuin-B remained unchanged when only phosphatebuffered saline (PBS) was administered. (A) A single fetuin-B ASO bolus decreased serum fetuin-B to 90 ± 10% (50 mg/kg, n = 3) and 74 ± 3% (100 mg/kg, n = 3), respectively. (B) Ten repetitive boli decreased serum fetuin-B to 33 ± 6% (50 mg/kg, n = 3) and 8 ± 6% (100 mg/kg, n = 12) at day 20, respectively. Each data point indicates mean ± SD.
plugs matching the birth dates of litters were not observed, and are therefore missing in Fig. 3J and L. Nevertheless, these females had obviously successfully mated. Figure 5A shows that the first litter size of the fetuin-B ASO-treated females was smaller than the first litter of PBS-injected mice (4.6 ± 2.3 versus 6.7 ± 1.8 pups per litter, respectively, n = 20, P = 0.04). However, the smaller litter size was only temporary and the size of the second litter of fetuin-B ASO-treated mice was similar to PBS-treated mice (7.6 ± 1.3 versus 6.7 ± 1.8 pups per litter, respectively, n = 18, P = 0.25). To reduce the number of experimental animals, PBS-treated females were only mated until they became pregnant for the first time. The weight of the first and second litter at weaning was 9.4 ± 1.4 g and 8.4 ± 1.4 g (Fig. 5B) and thus similar to values reported for the C57BL/6J strain by Jackson Laboratory (9.7 ± 1.9 g (male), 9.3 ± 1.7 g (female): The Jackson Laboratory, https://www.jax.org/jax-mice-and-services/strain-data-sheet-pages/ body-weight-chart-000664). To study if serum fetuin-B was influenced by previous ASO treatment of the mothers, serum fetuin-B was measured in pups at weaning (3 week old). The parental animals were Fetub +/− and therefore the offspring had all three possible genotypes.
Serum fetuin-B of the offspring corresponded to their respective genotype in that no fetuin-B protein could be detected in serum from Fetub −/− pups, 68 ± 18% of wildtype serum fetuin-B was detected in Fetub +/− pups, and 95 ± 13% in Fetub +/+ pups (Fig. 5C ).
Permissive serum fetuin-B range required for contraception
We repeated the ASO mediated serum fetuin-B down-regulation with five mice, and fertilized oocytes in vitro instead of natural mating. This experiment was designed to determine the permissive serum fetuin-B range required for contraception. In IVF the chance of fertilization is considerably increased in comparison to natural mating and thus would be informative to determine the permissive serum fetuin-B range required for contraception. After ovarian hormone stimulation cumulus-oocyte complexes were harvested and inseminated.
Oocytes from six mice each that were treated with control oligonucleotide or were untreated were used as control. Both had unchanged serum fetuin-B levels (Fig. 6A) . ASO-treated females in this experiment had a serum fetuin-B of 9-18 µg/ml. The concentration range allowed studying the association of serum fetuin-B and IVF rate. The IVF rate was assessed by the presence of 2-cell embryos 24 hours after insemination. ASO-treated females had an IVF rate of 27 ± 18% (14% to 57% in individual mice, Fig. 6B ). Thus, the fertilization rate following fetuin-B ASO injection with 100 mg/kg body weight was generally higher in vitro (by IVF) than in vivo after natural mating where only 1 out of 12 mice had become pregnant (8.3%). To determine the minimum serum fetuin-B required for fertilization we combined the serum fetuin-B level and matching fertilization rate of the in vivo and in vitro study (Fig. 6C) . In vivo mating without offspring was scored with a 0% fertilization rate and the one in vivo mating that had offspring (7 pups, Fig. 3M ) was scored with a 100% fertilization rate. Combined values indicate that a serum fetuin-B below 10 µg/ml should be associated with infertility, serum fetuin-B between 10 and 20 µg/ml should be associated with highly variable fertility, and serum fetuin-B of 20 µg/ml and above should be associated with full fertility. This corroborates the previous observation during the in vivo mating study where all mice with serum fetuin-B of 10 µg/ml and below failed to become pregnant, and all mice with 20 µg/ml serum fetuin-B and above became pregnant (Fig. 6A) . Collectively the data suggest that serum fetuin-B down-regulation to below 10 µg/ml prevented pregnancy, and serum fetuin-B above 20 µg/ml permitted pregnancy.
Oocytes from control oligonucleotide-treated mice had an IVF rate of 17 ± 8%, which was lower than the IVF rate of oocytes from untreated mice (40 ± 10%) despite similar serum fetuin-B concentrations. While the IVF rate of untreated mice was in the expected range of fertile mice, the reason for a decreased IVF rate in control oligonucleotide-treated mice remains to be elucidated.
Discussion
Female Fetub −/− mice are completely infertile because of premature ZP hardening (Dietzel et al., 2013) . In the absence of fetuin-B as an inhibitor, spuriously released ovastacin cleaves ZP2 into ZP2f thereby Figure 4 Fetuin-B ASO treatment led to reduced fetuin-B mRNA synthesis and increased aminotransferase activity. (A) Fetuin-B liver mRNA was significantly reduced in fetuin-B ASO-treated females in comparison to PBS-treated females. Fetuin-B mRNA expression of 6 mice each group is normalized to fetuin-B liver mRNA of PBStreated mice. Glycerinaldehyd-3-phosphate dehydrogenase (Gapdh) was used as housekeeping control gene. Two-tailed Student's t-test; ***P < 0.0001 (B) Alanine aminotransferase (ALT) and (C) aspartate aminotransferase (AST) activity was increased in females administered with ASO. Two-tailed Mann Whitney t-test; n.s. = not significant, **P = 0.009. causing definitive ZP hardening before fertilization. As a consequence no sperm is able to penetrate the ZP and fertilization cannot occur. Our demonstration that Fetub −/− , Astl −/− female mice are fertile despite the absence of fetuin-B underscores the specificity of fetuin-B as an inhibitor of ovastacin, and vice versa. Furthermore the Fetub −/− , Astl −/− mice provide genetic proof of a simple proteinase network consisting of a substrate (ZP2) processed by a proteinase (ovastacin), which is regulated by a proteinase inhibitor (fetuin-B), collectively regulating fertilization. This proteinase network is reminiscent of certain aspects of blood coagulation/fibrinolysis where a gelling substrate fibrin(ogen) is created by the action of the proteinase thrombin(ogen) and thereafter removed by the proteinase plasmin(ogen). Single deficiency of plasminogen was met with the expected thromboembolic disorder, while the loss of fibrinogen rescued mice from the pleiotropic effects of plasminogen deficiency (Bugge et al., 1995 (Bugge et al., , 1996 . High numbers of 2-cell embryos after IVF of oocytes from , Astl −/− females this protection would be largely absent due to an unhardened ZP or the complete absence of a ZP suggested by the presence of zona-free 2-cell embryos 24 hours post insemination. Embryos with a non-hardened ZP are readily absorbed by the oviduct epithelium. This also happens when the zona is mechanically removed or when the ZP lacks ZP1 (Modliński, 1970; Rankin et al., 1999 Rankin et al., , 2001 . Recently, Winuthayanon and coworkers described impaired ZP2 cleavage in mice with conditional deletion of the estrogen receptor α (ERα). Oocytes with impaired ZP2 cleavage resulting in incomplete ZP hardening were unable to develop into healthy embryos (Winuthayanon et al., 2015) . An alternative explanation for the variable litter size in Fetub −/− , Astl −/− females would be embryo abortion following polyspermy.
However, the observations in Fetub
, Astl −/− oocytes suggest that they had a non-hardened ZP, but did not sustain polyspermy. Oocytes with mutated, non-cleavable ZP2 also had no supernumerary sperm in oocytes suggesting that post-fertilization polyspermy block was independent of ZP2 cleavage (Gahlay et al., 2010) . Thus the role of the ZP as a barrier to polyspermy is controversial, whereas the permissive role of ZP hardening for successful embryo development and ). Fetuin-B deficient pups had no serum fetuin-B. Serum fetuin-B was determined by normalization to an untreated 3 week-old wildtype pup. Below the X-axis the number of pups and the respective mating cage are given. The mating cage corresponds to Fig. 3; (B, F) and (G) show the results of two successive litters. implantation gains further support by this study. Recent work showed that the rapid post-fertilization shedding of the oocyte-derived molecule Juno, the binding partner for the sperm-derived molecule Izumo, is in fact the critical event regulating sperm-oocyte binding and thus polyspermy (Bianchi et al., 2014) .
In summary, different mutated mouse lines underscored the essential role of the ZP during folliculogenesis (Zp2 (Rankin et al., 1996 (Rankin et al., , 2001 , oocyte fertilization (Fetub −/− ) (Dietzel et al., 2013) and passage down the oviduct (Zp1 (Rankin et al., 1999; Gahlay et al., 2010) . The absence of one or several of these players may impede proper ZP function leading into impaired fertility or complete infertility. Furthermore, we could observe an association between serum fetuin-B down-regulation and fertility. In the initial dose finding study, 50 mg/kg fetuin-B ASO down-regulated serum fetuin-B levels to 33 ± 6 µg/ml, but the treated mice still became pregnant following natural mating. One female treated with 100 mg/kg fetuin-B ASO had a down-regulated serum fetuin-B of 19 µg/ml, yet still became pregnant, while mice with serum fetuin-B lower than ca.10 µg/ml did not become pregnant upon natural mating. These observations suggested early on that a serum fetuin-B of 20 µg/ml should be sufficient for a successful fertilization. The variable IVF rate of between 14 and 57% observed in oocytes derived from females having 9-18 µg/ml serum fetuin-B neatly covered the critical range of ca.10-20 µg/ml serum fetuin-B, which seemed to be the tipping point for successful fertilization. Assuming a molecular weight of 50 kDa, 10 µg/ml serum fetuin-B corresponds to 200 nM. This value roughly corresponds to 2-to 3-fold the IC 50 value of ovastacin inhibition by fetuin-B, which was determined at 75 nM (Dietzel et al., 2013) . In summary, at least in mouse oocytes, a serum fetuin-B concentration of 10-20 µg/ml may determine in vivo and in vitro fertilization. This conclusion is further strengthened by a recent study demonstrating that use of IVF medium supplemented with 15 µg/ml rmfetuin-B resulted in twice the fertilization rate of cumulus cell-free oocytes than with fetuin-B-free IVF medium (Dietzel et al., 2016b) . Premature ZP hardening is a common complication in ART. Therefore, it might be worthwhile to use fetuin-B as an additive to prevent premature ZP hardening also in human IVF and thus to potentially increase the baby take home rate.
Female infertility is the only phenotypic consequence of fetuin-B deficiency in mice. Fetub −/− mice were comparable to wildtype mice in metabolic and functional parameters including body weight, blood chemistry, systolic and diastolic blood pressure, and pulse rate (Dietzel et al., 2013) . Thus fetuin-B down-regulation may be a promising birth control medication. Further improvement of the pharmacokinetics of fetuin-B ASO are nevertheless desirable. Even if the mice were indistinguishable from the PBS control mice in their behavior, 100 mg/kg fetuin-B ASO bolus is high compared to similar studies (Graham et al., 1998; Henry et al., 2004; Zanardi et al., 2012; Prakash et al., 2014) . After 3 weeks of repetitive 100 mg/kg fetuin-B ASO boli, we observed a modest increase of the aminotransferases ALT and AST compared to the PBS control mice, suggesting hepatotoxicity.
Ongoing improvements in ASO technology may reduce the required dose and regimen. Recently, Prakash and coworkers showed that triantennary N-acetyl galactosamine (GN3)-tagged ASO increased the down-regulating effect up to ten-fold in comparison to unmodified second generation gapmer ASO (Prakash et al., 2014) . GN3-ASO also did not increase aminotransferase levels. Black bars indicate that fertilization occurred in vitro or in vivo, white bars indicate that fertilization was prevented. Letters below the X-axis correspond to Fig. 3 . Serum fetuin-B (mean ± SD) of untreated hemizygous females (+/−, n = 16), control oligonucleotide (cOligo, n = 6) and PBS-treated females (n = 10) is depicted. (B) IVF rate of females treated with cOligo, fetuB ASO or were left untreated. Each dot represents the fertilization rate of pooled oocytes of two females (untreated and cOligo) or of one female (fetuB ASO). Three independent experiments are depicted. (C) Fertilization rate of females with 0-10 µg/ml serum fetuin-B (n = 9), 11-20 µg/ml (n = 7) and 21-100 µg/ml (n = 6) are depicted. Data points represent individual fertilization rates, except in the group of 21-100 µg/ml where fertilization rate of pooled oocytes (n = 2) is plotted. Bar at the right represents corresponding fertilization rate of each group in total.
A contraceptive medication should be well tolerated and provide a complete and reversible prevention of pregnancy. Further studies analyzing the balance between a sufficient fetuin-B down-regulation and tolerable side effects are required to improve safety before transfer of the fetuin-B/ovastacin system into human reproductive biology can be considered. The fact that increasing serum fetuin-B during hormonal ovarian stimulation was associated with an increased IVF rate in women raises hopes that the ovastacin/fetuin-B system may indeed also be exploited for contraception in humans (Floehr et al., 2016) . Interestingly, serum fetuin-B in humans is considerably lower (onetenth) than in mice (Dietzel et al., 2013; Floehr et al., 2016) . The homology of mouse and human fetuin-B (61%, Olivier et al., 2000) and ovastacin (69-78%, Quesada et al., 2004; Pires et al., 2013) suggest that human fetuin-B should be a potent ovastacin inhibitor in vivo, as was shown for mouse fetuin-B. Consequently, the human ovastacin/ fetuin-B ZP2 proteinase network may serve a druggable target for non-hormonal contraception in women.
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